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What Has Happened Since Chakrabarty?
Jane M. Marciniszyn*
I. Introduction
"Biotechnology" refers to the use of biological organisms cast in the role of
producers or manufacturers of useful goods. Biotechnology is based on the
use of gene-splicing or recombinant DNA, to produce new products,
cheaper products or purer products. Congress' Office of Technology As-
sessment has predicted that before the turn of the century, annual sales of
chemicals and drugs that are produced by gene-splicing could exceed fifteen
billion dollars.2
Sales of products which have arisen from biotechnology will come from
virtually every area of manufacturing. 3 Eleven years ago it would have
seemed implausible "that by 1984 an incredible $2.5 billion dollars would
have been invested in setting up more than one hundred new companies
dedicated to pioneering new products from biotechnology. "' Today, there
are 700 U.S. companies engaged in biotechnology.'
New companies and older companies expanding into this area have relied
on the Patent Act of 1952 to protect their investment. 6 This Act allows an in-
ventor to exclude all others from making, using, or selling his invention for
seventeen years. 7 Arthur R. Whale, in commenting on the pros and cons of
the patentability of micro-organisms, stated:
It is conventional wisdom that the patent system is designed to un-
dergird the investment in pushing technology forward. The patent
system is innovation-oriented. And (sic) it functions most effectively in
the expensive, breakthrough technologies, where uncertainties of suc-
* B.S., M.S., American University; J.D., Cleveland-Marshall College of Law. I wish to thank my
husband, Dr. Joseph P. Marciniszyn and Richard Egan, Esq., Adjunct Professor, Cleveland-
Marshall College of Law, for their contributions in preparation and analysis of this article.
'The DNA which results from the insertion of a whole or partial chain of DNA not originally/
biologically present in that chain. STEDMAN'S MEDICAL DICrIONARY 1207 (5th ed. 1982). For a more
detailed discussion of molecular biology, see Note, Building a Better Bacterium: Genetic Engineer-
ing and the Patent Law After Diamond v. Chakrabarty, 81 COLOM. L. REv. 159, 165-67 (1981).
2Biotech Comes of Age, Bus. WEEK, Jan. 23, 1984, at 84-85 [hereinafter Biotech].
31d. at85.
41d. at84.
'Fenyvesi, Federal Rules May Trigger Biotech Boom, U.S. NEws & WORLD REP., July 14, 1986, at
58.
635 U.S.C. § 8 1-376 (1976). Biotechnology companies have swamped the United States Pat-
ent and Trademark Office with over a thousand patent applications. Biotech, supra note 2, at 86.
735 U.S.C. §154 (1976).
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cess or payback abound. If, in assessing the risk of commitment, the
penalties of failure outweigh the prizes of success, the prudent money
will go elsewhere. The patent system moves the equation to the right,
not by better assuring success (for only public needs and market values
can do that), but by aiding success through offering the innovator a
temporary respite from non-innovative copying. However faulted and
flawed our system might be, only the most compelling legal logic
should deny this country its benefits in a nascent technology full of
promise for so much good.8
II. The Chakrabarty Decision
In 1980, the United States Supreme Court interpreted the scope of patent-
able subject matter, in the landmark case of Diamond v. Chakrabarty.9 The
Court held that a live, human-made microorganism is patentable subject
matter under a statute providing for the issuance of a patent to a person who
invents or discovers "any" new and useful "manufacture" or "composition
of matter." 10
In June, 1972, Ananda M. Chakrabarty, a microbiologist, filed a patent
application assigned to the General Electric Company, asserting thirty-six
claims relating to his human-made, genetically engineered Pseudomonas bac-
terium. Chakrabarty had created the bacterium by manipulating four rings
of DNA plasmids from different bacteria strains into one host bacterium."
These plasmids would replicate when the host replicated. A super strain
was created which would continue to reproduce its new self.
The new Pseudomonas bacterium was capable of degrading four different
components of crude oil. The host Pseudomonas bacterium itself had no ca-
pacity for degrading oil. Each of the naturally occurring bacterial plasmids
used to manufacture the new bacterium was capable of degrading only one
component of crude oil. Chakrabarty sought to patent his microorganism
'Whale, Patentability of Microorganisms (Introduction), 7 AM. PAT. L.A. Q.J. 172, 174 (1979).
9447 U.S. 303 (1980).
1Id.
"In bacteria, plasmids are circular DNA molecules that reproduce themselves and are thus
conserved, apart from the chromosome, through successive cell divisions; heredity units physi-
cally separate from the chromosomes of the cell. THE SLOANE-DORLAND ANNOTATED MEDICAL-
LEGAL DICrIONARY 555 (1987). For a more detailed discussion, see Novick, Plasmids, Sa. AM.,
Dec. 1980, at 102.
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because this property is possessed by no naturally occurring bacterium and
because this new microorganism is capable of mass production and use for
more efficient and rapid control of destructive oil spills.
Chakrabarty's claims on the bacterium were rejected by the patent exam-
iner on two grounds:12 "1. that microorganisms are 'products of nature' and
2. that as living things they are not patentable subject matter under section
101 of the Patent Act of 1952."" Chakrabarty appealed the rejection of his
claim to the Patent Office Board of Appeals (Board). The Board affirmed the
examiner but only on the second ground.4 The Court of Customs and Patent
Appeals (C.C.P.A.) reversed, concluding that the fact that microorganisms
are alive is without legal significance for purposes of the patent laws. 5 The
United States Supreme Court granted certiorari in 1979.6
Article 1, section 8, clause 8 of the United States Constitution provides
that "Congress shall have power [to legislate] . . . to promote the Progress
of Science and useful Arts, by securing for limited Times to Authors and In-
ventors the exclusive Right to their respective Writings and Discoveries."
Clause 8 was intended to confer on inventors an exclusive right of owner-
ship and use for a finite time. This right served as a reward for the benefit the
public derived from the efforts of an individual, and as a stimulus to creativ-
ity. Individual reward is, of course, the inducement without which little
"Progress of Science and useful Arts" could be expected. In 1790, Congress
exercised this delegated power and enacted the Patent Act of 1790. In 1793,
1836, 1870, 1874, 1930 and 1952, amendments were made to the Patent Act.
As Chief Justice Marshall expressed, "to promote the progress of useful
arts, is the interest and policy of every enlightened government."17 "The au-
thority of Congress is exercised in the hope that the productive effort
thereby fostered will have a positive effect on society through the introduc-
tion of new products and processes of manufacture into the economy, and
the emanations by way of increased employment and better lives for our citi-
zens. ",8
"Chakrabarty, 447 U.S. at 306.
13Id.
141d.
"In re Chakrabarty, 571 F.2d 40,43 (C.C.P.A. 1978).
6Diamond v. Chakrabarty, 444 U.S. 924 (1979).
"
7Grant v. Raymond, 31 U.S. (6 Pet.) 218, 241 (1832).
"Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 480 (1974).
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The Supreme Court in Chakrabarty defined the issue as whether Chakra-
barty's microorganism, constituted a "manufacture" or "composition of
matter" within the meaning of section 101 of the Patent Act of 1952."
In determining the scope of section 101 the Supreme Court began with the
language of the statute, interpreted words as taking their ordinary, contem-
porary common meaning, and was careful not to read into the patent laws
limitations and conditions which the legislature had not expressed.2
The Supreme Court read the term "manufacture" in section 101 in accord-
ance with its dictionary definition to mean "the production of articles for use
from raw or prepared materials by giving to these materials new forms,
qualities, properties or combinations whether by hand-labor or by machin-
ery."21 "Composition of matter" was construed consistently with its com-
mon usage to include "all compositions of two or more substances
and .. .all composite articles, whether they be the result of chemical union,
or of mechanical mixture, or whether they be gases, fluids, powders or
solids."2
When Congress first selected the word "any" for section 101 of the Patent
Act it intended that the statute be given wide scope, as reflected by the rele-
vant legislative history.21 The Patent Act was drafted by Thomas Jefferson
and embodied his philosophy that "ingenuity should receive a liberal en-
couragement. "2 The Committee Reports accompanying the 1952 Act stated
"[tihat Congress intended [the] statutory subject matter to include anything
under the sun that is made by man. "
The Supreme Court has created limits to patentable subject matter. The
laws of nature, physical phenomena, and abstract ideas are not patentable
as these discoveries are "manifestations of. .. nature, free to all men and
reserved exclusively to none."6
"Chakrabarty, 447 U.S. at 307. 35 U.S.C. § 101 (1976) provides: Whoever invents or discovers
any new and useful process, machine, manufacture, or composition of matter, or any new and
useful improvement thereof, may obtain a patent therefore, subject to the conditions and re-
quirements of this title.
'Chakrabarty, 447 U.S. at 308.
"American Fruit Growers, Inc. v. Brogdex Co., 283 U.S. 1, 11 (1930).
"Shell Dev. Co. v. Watson, 149 F. Supp. 279, 280 (D.C. 1957).
3Chakrabarty, 447 U.S. at 308.
241d.
2S. REP_ No. 1979, 82d Cong., 2d Sess. 5 (1952); H.R. REP_ No. 1923, 82d Cong., 2d Sess. 6
(1952).
"See Parker v. Flook, 437 U.S. 584 (1978); Gottschalk v. Benson, 409 U.S. 63 (1972); Funk
Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948).
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Judged in this light, the Supreme Court found that Chakrabarty's micro-
organism "plainly qualifies as patentable subject matter."z Chakrabarty's
claim "is not to a hitherto unknown natural phenomenon but to a nonna-
turally occurring manufacture or composition of matter - a product of hu-
man ingenuity having a distinctive name, character or use."2
In Funk Brothers Seed Co. v. Kalo Inoculant Co.," decided in 1948, the Su-
preme Court invalidated a microbiological patent because the subject matter
was a "product of nature." The subject matter was a mixture of several
known strains of nitrogen-fixing Rhizopus bacteria. This mixture was consid-
ered useful because it could be used to inoculate several legumes rather than
having a separate Rhizopus for a particular legume. The court distinguished
Funk from Chakrabarty by noting that Funk made a mixture of bacteria
wherein each bacterium in the culture would not inhibit the desired result of
the others when used to inoculate seeds of leguminous plants. The mixed
culture was nonpatentable, as the patentee had discovered "only some of
the handiwork of nature."" No species acquired a different use. By contrast,
Chakrabarty's bacterium was a new bacterium with markedly different char-
acteristics from those found in nature. 31 "His discovery is not nature's handi-
work but his own; accordingly it is patentable subject matter under section
101. 13
The companion case to Chakrabarty was In re Bergy.1 The examiner re-
jected the Bergy patent application on the basis that the microorganism cul-
ture, Streptomyces vellosus, was a "product of nature" and not within the sub-
ject matter of section 101 of the Patent Act of 1952.3 Appeal to the Board
affirmed the examiner's rejection, but the Board switched the basis of rejec-
tion: The Board concluded that section 101 precludes patenting any thing
living.35
The C.C.P.A. reversed both the examiner and the Board and found the
rejection based on "product of nature" to be wholly lacking merit.2 The cul-
vChakrabarty, 447 U.S. at 309.
2id.
29333 U.S. 127, 131 (1948).
3id.
3"Chakrabarty, 447 U.S. at 310.
3Id.
-596 F.2d 952 (C.C.P.A. 1979).
'Ex parte Bergy, 197 U.S.P.Q. (BNA) 78 (June 22,1976).
31Id.
In re Bergy, 563 F.2d 1031 (C.C.P.A. 1977).
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ture "does not exist in, is not found in, and is not a product of, nature."3 It is
man-made and can be produced only under carefully controlled laboratory
conditions.38 In addition, the C.C.P.A. stated that the claim presented statu-
tory subject matter and should not have been rejected on the ground that it
was a living organism. The United States Supreme Court granted certiorari
but the appealed claim in the Bergy application was subsequently cancelled
by the applicant in the Patent and Trademark Office. A motion was filed in
the Supreme Court to dismiss the appeal as moot. The Supreme Court did
dismiss Bergy.40 Thus, Diamond v. Chakrabarty was left to be decided by the
Supreme Court.
The inventor in Bergy had developed a purified culture of an old microor-
ganism. He did not create a new one. This old microorganism, Streptomyces
vellosus, was made capable of markedly increased production of an impor-
tant antibiotic, lincomycin, without the concomitant production of linoco-
mycin B. This microorganism did not exist as a pure culture in nature. It ex-
isted in the soil as a complex colony of microorganisms and this naturally
occurring complex "could not be used to produce a desired product under
any known fermentation conditions."4 1 It was only by the discovery and
skills of the microbiologist, that biologically pure cultures of microorganisms
came into existence. The Bergy naturally-occurring microorganism was
quite useless before it was purified.
When the "product of nature" rejection is used to reject as patentable the
claiming of laws of nature, such as gravity or electricity, then there is long-
standing judicial precedent for support.3 However, when the "product of
nature" is used to reject a claim to an entity, which as claimed does not occur
in nature and cannot be considered a law of nature, this rejection could be
ripe for reversal based on Bergy and Chakrabarty. Early in the case history of
Chakrabarty, the Board expressly reversed the examiner; that withholding
the Chakrabarty patent could not be based on the theory of a "product of
nature" rejection, that one cannot take from the public that which the public
already has the right to enjoy.43
371d.
3Id.
NId.
-444 U.S. 1028 (1980).
4
11n reBergy, 596 F.2d 952, 972 (C.C.P.A. 1979).
1Id. at 952.
4
1n re Chakrabarty, 571 F.2d 40, 42 (C.C.P.A. 1978).
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The Supreme Court first defined "product of nature" in American Fruit
Growers, Inc. v. Brogdex Co.I In this case, fruit was washed in borax, such that
the rind of which became "impregnated with borax, through immersion in a
solution, and thereby rendered resistant to blue mold decay."4 ' The
C.C.P.A. stated that the product, fruit, with its rind impregnated with bo-
rax, was an article of manufacture since the fruit was
the result of a process which is defined and described and not a natural
product. The product is a combination of the natural fruit and a borax
component carried by the rind or skin in an amount sufficient to render
the fruit resistant to decay. The completed article is not found in nature
and is thus an article of manufacture.6
The Supreme Court found the C.C.P.A.'s position untenable.
Addition of borax to the rind of natural fruit does not produce from
the raw material an article for use which possesses a new or distinctive
form, quality or property. The added substance only protects the natu-
ral article against deterioration by inhibiting development of extra-
neous spores upon the rind. There is no change in the name, appear-
ance, or general character of the fruit. It remains a fresh orange fit only
for the same beneficial use as theretofore.4
All that American Fruit requires for a patent is that the new article (fruit)
possess "a new or distinctive form, quality or property" or "name, appear-
ance or general character."4
In contrast to American Fruit, the Chakrabarty microorganism was a to-
tally new super strain of bacterium created by the microbiologist who geneti-
cally engineered the insertion of four plasmids into a host bacterium. It was a
product of human ingenuity having a distinctive name, character, and use.
In comparison, the Bergy microorganism was a biologically pure culture of
an otherwise unmodified microorganism capable of producing recoverable
quantities of a useful antibiotic.
Even though the microorganism per se existed in soil, it could not therein
"be used to produce the desired product under any known fermentation
-283 U.S. 1 (1931).
'1ld. at 11.
4Id.
vId. at 11-12.
"Id. at 12-13.
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condition."0 In contrast, the borax treatment gave the oranges no new bene-
ficial use; it merely protected the orange against deterioration by blue mold.
The Bergy microorganism, however, was useless for production of lincomy-
cin before the purification. This change in usefulness must be the type of
new or distinctive quality or property that is required for a manufacture to be
patentable purified natural product as envisioned by American Fruit. "The
patent law does not proscribe patenting things which exist in nature, only
the latter are things which all men may freely enjoy and which cannot be
withdrawn from the public domain through patents."5
III. What has happened since Chakrabarty?
Subsequent to Chakrabarty, the Board found maize plant technology to be
within the subject matter of section 101 of the Patent Act of 1952.51 The claims
in Ex parte Hibberd relate to maize seed, maize plants capable of producing
maize seed, and tissue culture capable of generating a plant capable of pro-
ducing seeds containing an increased amount of tryptophan.Y
The examiner rejected the claims solely under section 101, as the subject
matter of seeds and plants is within the purview of the Plant Variety Protec-
tion Act of 1970 (PVPA).53 The tissue culture patent application was rejected
as subject matter inappropriate for protection under section 101 because it
was in the purview of the Plant Patent Act of 1930 (PPA).M The examiner
allowed patents for the hybrid seeds and plants." The examiner's position
was that the plant-specific Acts (PPA and PVPA) are exclusive forms of pro-
tection for plant life covered by those Acts. 6
The Board held that the scope of patentable subject matter under section
101 of the Patent Act of 1952 has not been narrowed or restricted by the pas-
sage of PPA and PVPA, nor do these plant-specific Acts represent exclusive
1Bergy, 596 F.2d at 972.
5Dunner & Lipsey, The Patentability of Life Forms, New Technologies and Other Flooks of Nature, 7
Am. PAT. L.A. Q.J. 190 (1979).
"
1Ex parte Hibberd, 227 U.S.P.Q. (BNA) 443 (Sept. 24, 1985).
2Id.
51Id. at 444.
435 U.S.C. § 161 (1976).
5
'Ex parte Hibberd, 227 U.S.P.Q. (BNA) 444 n. 1 (Sept. 24, 1985).
'Id. at 444.
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forms of protection for plant life covered therein.5 The language of the PPA
and PVPA does not exclude plant life, nor do the Acts' legislative histories
exclude plant life as subject matter from protection under section 101 even
though plant-specific Acts protect these plant forms."
The Hibberd Court noted that the Supreme Court in Chakrabarty thor-
oughly examined the legislative history and purpose of both the PPA and
PVPA. The Court stated that "prior to 1930, two factors were thought to re-
move plants from patent protection." 9 The first was the belief that plants,
even though artificially bred "were products of nature not subject to patent
protection."60 The second was the fact that plants were not thought to be
amenable to the "written description" requirements of the patent laws. 6 The
Supreme Court in Chakrabarty stated that "in enacting the PPA, Congress
addressed both of these concerns."" It explained at length its belief that the
work of the plant breeder "in aid of nature" was a patentable invention, and
it relaxed the written description requirement in favor of "a
description... as complete as is reasonably possible."1 The Hibberd Court
felt the Supreme Court's analysis in Chakrabarty made it clear that these Acts
were to extend patent protection to plant breeders under the PPA and PVPA
when the two factors existed."
The Hibberd Court reiterated the Borden Rule which provides that when
there are two acts on the same subject, the rule is to give effect to both unless
there is such a "positive repugnancy" or "irreconcilable conflict" that the
statutes cannot coexist." The Board found no "positive repugnancy" nor "ir-
reconcilable conflict" between section 101 and the plant-specific Acts even
though the subject matter under section 101 overlapped with the subject
matter protectable under the plant-specific Acts. "[T]he overlap can be
viewed as an indication that Congress intended the availability of both
modes of protection.""
5MId.
5SId.
'Diamond v. Chakrabarty, 447 U.S. 311 (1980).
6Id.
6'Id. at 312.
6Id.
6Id.
"Ex parte Hibberd, 227 U.S.P.Q. (BNA) 443, 445 (Sept. 24,1985).
'United States v. Borden Co., 308 U.S. 189, 198-99 (1939).
"Ex parte Hibberd, 227 U.S.P.Q. (BNA) 443, 446 (Sept. 24, 1985).
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IV. Expanding Biotechnology
It is noteworthy that without changes in legislation the judiciary has al-
tered the interpretation of statutory subject matter to adapt to the develop-
ments in technology. As discussed above, both plant and animal technology
are now held firmly within the scope of section 101 of the Patent Act of 1952.
Ownership of patents in the biotechnology area has increased the commer-
cial potential of biotechnology. 67
Recombinant-DNA and gene-splicing can be used to turn the body's pro-
teins into potential drugs and provide new routes for the industrial chemist.
Biotech industries have successfully used their expertise to produce prod-
ucts ranging from human insulin for diabetes (instead of animal insulin) to
new varieties of corn and tomatoes which are both hardier and more nutri-
tious. 6s
Before they can be marketed, genetically engineered pharmaceuticals,
food additives and cosmetics must be approved by the Food and Drug Ad-
ministration (FDA). The FDA has approved five biotechnology therapeutics:
human insulin (1982),6 human growth hormone (1985),7 alpha interferon
(1986),7 monoclonal antibody (1986) n and hepatitis B vaccine (1986). 3
Genentech, Inc.'s human insulin, licensed to Eli Lilly and Co., became the
first recombinant-DNA drug to reach the market. 74 Genentech markets the
second FDA approved therapeutic, human growth hormone, under the tra-
dename of Protropin.7 This is the first drug taken from discovery to market
six years later by a biotechnology company. Genentech sought FDA ap-
proval to market the human growth hormone in 1983.76 Protropin is used to
67For a discussion of pending federal legislation which offers the hope of renewed incentives
for new animal health care products development, see Research Encouragement Offered - But
Heavily Qualified - In Legislation, 7 Animal Drug News (Animal Health Inst.) No. 4, at 2 (July-
Aug. 1986).
6Biotech, supra note 2, at 84.
69FDA Approves New Drug to Halt Rejection of Kidney Transplants, Cleveland Plain Dealer, June
20, 1986, at 5-A, col. 1 [hereinafter FDA Approves New Drug].
'"Id. See also Hamilton, Biotech's First Superstar, Bus. WEEK, Apr. 14, 1986, at 68, 69.
ninterferon Approved for Marketing by FDA, CHEM. & ENG'G NEWS, June 9, 1986, at 7 [hereinafter
Interferon].
"FDA Approves New Drug, supra note 69, at 5-A.
7Lab-produced Vaccine Against Hepatitis Ok'd, Cleveland Plain Dealer, July 24, 1986, at 12-A,
col. 1 [hereinafter Vaccine].
7'Hamilton, supra note 70, at 69.
7id.
761d.
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counteract a deficiency that causes some children to become dwarfs.' In
June, 1986, Genentech sought FDA approval to expand the use of Protropin
to treat short stature associated with Turner's Syndrome, a chromosomal
disorder which affects approximately 8,000 young girls.'
In June, 1986, the FDA issued its first approval to market a recombinant
DNA product for use against cancer.7 The product, alpha interferon, which
is the third FDA approved therapeutic, will be marketed by two companies,
Hoffman-La Roche and Schering-Plough."0 Both companies appeared to be
heading for a clash over patent rights for their slightly different versions of
alpha interferon. However, in May, 1985, the two firms agreed to cross-
license the rights in the United States, thus avoiding both costly patent liti-
gation and a delay in the introduction of the product.8'
Interferon is the first of a new generation of synthetic anticancer agents,
known as biologicals. These natural substances exist in small quantities in
the body, but now can be mass produced through genetic engineering.3 La
Roche developed its alpha interferon, tradenamed Roferon-A, in collabora-
tion with Genentech, and Schering-Plough licensed its product, Intron A,
from Biogen.1 The FDA approved both versions specifically for the treat-
ment of hairy cell leukemia, a disease which affects 1000 Americans.'' At
present these companies are seeking FDA approval to expand the use of al-
pha interferon against multiple myeloma, a cancer that attacks plasma cells;
Kaposi's sarcoma, a cancer associated with AIDS; malignant meloma, a skin
cancer; and venereal warts. ' The companies are also testing alpha interferon
for treatment of non-Hodgkin's lymphoma, a lymph gland cancer; laryngeal
papillomatosis, the growth of warts in the throat; and the common cold. 17
Of great importance to the developers of recombinant DNA therapeutics
was the fact that the FDA approved alpha interferon within six months after
77Biotech, supra note 2, at 84.
7GENENTEcH, INC., SECOND QUARTER REPORT 1 (1986).
NInterferon, supra note 71, at 7.
'id.
81id
.
81A Cancer Drug Wins Its Spurs, U.S. NEWS & WORLDREP., June 16, 1986, at 7.
8i3d.
"Interferon, supra note 71, at 7.
85d.
Id.
871d.
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the companies filed new drug applications; even on fast-track, FDA ap-
proval normally takes an average of two years."
The fourth bioengineered drug to receive FDA approval is monoclonal
antibody, which is being used to reverse the rejection of newly transplanted
kidneys.8 Each year about 7,000 Americans receive kidney transplants and
about two-thirds have symptoms of acute rejection.Y Unchecked, the rejec-
tion will lead to a shutdown of renal function and the patient's return to
dialysis.9 Federal health officials have said the new drug could also make
kidneys available to more people.7 The approval is the first world-wide for
therapeutic use of a product of animal origin developed by biotechnology."
Monoclonal antibody is produced by fusing and cloning cells in a laboratory
and not through the process of gene-splicing." It is marketed by Ortho Phar-
maceutical Corporation under the tradename, Orthoclone OKT3.9
Until recently, monoclonal antibody technology has been used primarily
for diagnostic purposes, such as pregnancy testing, AIDS screening and tu-
mor detection." Research has indicated, however, that monoclonal anti-
bodies may help purge bone marrow of tumor cells, thus enhancing the ef-
fectiveness of bone marrow transplants. 7
In July, 1986, the FDA approved the first commercialized genetically engi-
neered human vaccine, Recombivax HB. The vaccine, which prevents hepa-
titis B, is administered by three injections over an eight month period to
those considered at risk of contracting hepatitis B from contaminated blood,
semen, or saliva." Recombivax HB is replacing the hepatitis vaccine made
from human blood components.' It is estimated that seventy percent of
those people who need inoculations do not get them out of fear of AIDS con-
'Id. See also Is Red Tape Tying Up High Tech? Keeping the Genie in the Bottle, U.S. NEWS & WoRLD
REP., Apr. 21, 1986, at 50.
'FDA Approves New Drug, supra note 69, at 5-A.
9ld.
91Id.
"ld.
"Id.
"Id.
"ld.91Id.
n3d.
"Vaccine, supra note 73, at 12-A.
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tamination.1"" Recombivax HB contains no blood ingredients and is pro-
duced by fermentation and modification of a special type of yeast. °0
Hepatitis B can lead to liver cancer and cirrhosis of the liver. 102The vaccine
is expected to prevent many cases of these diseases, which annually claim
the lives of approximately 5,000 Americans. 1 The vaccine was developed
with gene-splicing techniques."' Scientists hope to use these techniques to
develop similar vaccines against malaria, snail fever, and other diseases that
result in millions of deaths throughout the world each year.10
Genentech is presently seeking approval of a tissue type plasminogen ac-
tivator (t-PA), tradename Activase.11 Genentech received its first patent on
this drug in Britain in February, 1986."'7 Investors believe that Activase will
be the second billion dollar drug.1 FDA approval is expected in 1987.10 Ac-
tivase, a gene-splicing protein, sparks enzymes which will dissolve blood
dots almost immediately in the treatment of heart attacks.
A report given at the American College of Cardiology in March, 1986, in-
dicated that Activase cleared blocked arteries in seventy-five percent of the
patients treated."0 These findings were so significant that the National Insti-
tute of Health has decided it would be unethical to withhold Activase from
the patients who were getting placebos in the clinical trials."' Now every pa-
tient in the trials will receive Activase as standard therapy. 12 The results of
these trials will be submitted to FDA as part of the Product License Applica-
tion. "1
An antiviral drug, Azidothymidine (AZT) is the first drug shown to have
prolonged the survival of AIDS patients. 4 The drug was developed and
10Id.
"'1Id.
""2Id.
""3Id.
"'ild.,051d.
16GENENTECH, INc., FRsT QuARTER REPORT 1 (1986) [hereinafter FIRsT QUARTER REPORTJ.
""Hamilton, supra note 70, at 69.
"'SmithKline Beckman Corp.'s antiulcer drug Tagamet was the first. Id.
"'9Webber, Biotechnology Stocks Outraced Stock Market in First Half, CHEM. & ENG'G NEWs, July
14, 1986, at 17.
"°F1T QuARTER REPORT, supra note 106, at 1.
"'Id.
1121d
.
113Id.
"'Experimental Drug for AIDS Shows Promise, Officials Say, Cleveland Plain Dealer, Sept. 19,
1986, at 8-A, col. 1.
JOURNAL OF LAW AND HEALTH
manufactured by the Burroughs Wellcome Company."'5 AZT was originally
obtained from the sperm of herring and salmon. Today, methods have been
developed to produce it synthetically through genetic engineering." 6 While
most drugs take eight to ten years before the FDA clears them for general
use, AZT emerged from testing in two years. 17
Although AZT shows major promise in the battle against AIDS, it is not a
cure."8 AZT is now in the same class as other drugs whose trials were sus-
pended when patients dearly improved."9 The reason for the suspension
was to allow those who took part in the study, but who had received a pla-
cebo, to begin taking AZT. The present course is to increase the size of the
test group for new clinical trials.
In the race between the search for a cure and the spread of the nation's
most feared infectious disease, doctors hope that advances can be made to
stem the new threat of AIDS striking beyond-risk groups to the general pop-
ulation. Genentech is investigating the development of an AIDS vaccine
which could prevent a widespread epidemic and eliminate the threat of the
disease.' 0 The results of Genentech's in vitro experiments have been encour-
aging, and the use of an animal model, such as the chimpanzee, will be a
necessary next step.12'
A new form of interferon was patented during the first week of October,
1986, for Damon Biotech, Inc. 22 Tradenamed Interferon Epsilon, the new
form is produced from human epithelial cells and has a marked anti-viral
activity in such cells. 1' Epithelial cells are abundant in the body and are ma-
jor targets of virus infection and cancer. 24 The invention's use is still in the
developmental stages. 25
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Biotechnology is also important in the area of livestock production. At
least ninety-two companies in the United States are now engaged in veteri-
nary biotechnology activity of some type, and 171 separate veterinary
biotechnology projects are known to be underway in industry.'" Research
efforts are currently centered on developing growth hormones, vaccines,
and what is known as "probes and vectors. " 1 The latter category includes
products and processes that use biotechnology to diagnose disease, as well
as regulate and enhance the animal's immune system. 2
The bovine growth hormone (bGh) can increase milk yields up to twenty-
five percent; field trials of this recombinant DNA growth hormone are now
underway to demonstrate their safety and effectiveness." Use of the bGh is
expected to cause an increase in milk production and will eventually lower
the price of milk.131 The use of bGh is not without controversy, however.
Jeremy Rifkin, an avowed foe of genetic engineering, has petitioned the
FDA to block approval of the hormone . 13 Rifkin wants to compel the agency
to perform an environmental impact statement as part of its review process,
on the grounds that the hormone will affect land use and the cow's "internal
environment."'32 He asserts that cows injected with the hormone will be sub-
ject to more stress and disease. The Humane Society of the United States
was among co-signers of the petition. 13
At a recent United States House of Representative hearing, representa-
tives of the four hormone manufacturers of bGh argued that the hormone
will help the farmer stay competitive, and that, over the short-term, treated
cows do not differ from untreated controls with regard to disease, temper-
ment and reproduction. m Long-term studies are still being conducted. 13
FDA approval of the hormone is not expected until 1989 or 1990.'36
A recombinant DNA vaccine for pseudo-rabies is now available, and vac-
cines for foot-and-mouth disease, scours and coccidiosis may be available
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between 1988 and 1991.137 Jeremy Rifkin is also opposing the use of pseudo-
rabies vaccine. 1
Animal health officials in Minnesota claim that pseudo-rabies is costing
hog farmers one million dollars a month. Nationally, it is estimated that
about ten percent of the country's fifty-four million swine are infected with
the pseudo-rabies virus. The annual cost to pork producers may be as high
as sixty million dollars.13
In comparing the present state of veterinary biotechnology with the pros-
pects for the future, growth hormones and vaccines will continue to domi-
nate research activities. However, inventors are moving in all directions,
producing an astounding number of useful products including pharmaceu-
ticals, improved plant varieties, pesticides and chemical feedstocks.
Moreover, gene-splicing will lead to patent applications on living organ-
isms more complex than a virus or bacterium. It could eventually lead to ge-
netically engineered humans. A Canadian Patent Appeal Board stated in the
case of In re Abitibi:
If an inventor creates a new and unobvious insect which did not exist
before (and thus is not a product of nature), and can recreate it uni-
formly and at will, and it is useful (for example to destroy, the spruce
bud worm), then it is every bit as much a new tool of man as a microor-
ganism. With still higher life forms it is of course less likely that the
inventor will be able to reproduce it at will and consistently, as more
complex life forms tend to vary more from individual to individual.
But, if it eventually becomes possible to achieve such a result, and the
other requirements of patentability are met, we do not see why it
should be treated differently.140
Thus far both plant and animal technology are within the subject matter
of section 101 of the Patent Act of 1952. The frontiers of biotechnology are yet
to be explored. With Chakrabarty as the basis, man is finding the capability of
making anything and everything - all possibly patentable. As reiterated by
Chief Justice Warren Burger, statutory subject matter should "include any-
thing under the sun that is made by man."1 4'
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